ClinicalTrials.gg
CompletedNCT00745875Updated Jun 6, 2012Results posted

ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study

A Phase 2 interventional study of ZD4054 and Pemetrexed in Non Small Cell Lung Cancer and Lung Cancer, sponsored by AstraZeneca. Completed at 13 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-06.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 25 open to participants now, 78 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.

Enrollment
93rd of 137
66 · median 152
Started
2008
with 1 other
Phase 2
38 of 209
2 open now
Registered
27th of 209
by date

Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 93rd largest by enrollment of the 137 interventional ones that give a count, is one of 2 that started in 2008, is one of 38 in phase 2, and was the 27th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

25 of the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, or all of them as a file.
02

Study summary

The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment with pemetrexed alone

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Lung Cancer

Keywords

  • NSCLC
  • Phase II
  • ZD4054
  • Pemetrexed
  • Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed locally advanced or NSCLC on entry into study suitable for pemetrexed therapy
  • Patients that meet one of the following criteria: - progressed following one prior platinum-based chemotherapy regimen for locally advanced or metastatic disease; -progressed within 6 months of platinum-based chemotherapy
  • of > 12 weeks

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with pemetrexed in the last 12 months.
  • Prior therapy with an ET receptor antagonist
  • Any recent surgery, unhealed surgical incision, severe concomitant medical condition (eg, unstable cardiac, hepatic or renal disease) or significant laboratory finding which makes it undesirable for the patient to participate
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    1

    ZD4054 + Pemetrexed

    Drug: ZD4054 · Drug: Pemetrexed

  • Placebo comparator
    2

    ZD4054 matched placebo + pemetrexed

    Drug: Pemetrexed · Drug: Placebo

Interventions

  • DrugZD4054

    10mg oral tablet, once daily

    Also known as: Zibotentan

  • 500mg2/m IV infusion

    Also known as: Alimta

  • DrugPlacebo

    10mg oral tablet, once daily

06

What researchers measure

Primary outcomes

  1. Time to Death

    Median time (in days) from randomisation until death using the Kaplan-Meier method (Calculator for survival probability)

    Time frame: Patients were followed up for survival every week for the first 3 weeks then every 3 weeks whilst on study medication until the data cut-off (17th January 2010).

Secondary outcomes

  1. Progression-free Survival

    Median time (in days) from randomisation until disease progression/death using the Kaplan-Meier method

    Time frame: Tumour assessments for progression were performed at screening, every 3 weeks, Mandatory Tumour Assessment Visit (19 August 2009 ± 3 days), treatment discontinuation

07

Results

Posted Jun 6, 2012

Participant flow

80 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) where the histology was not predominantly of squamous type were recruited between 12th August 2008 and 3rd June 2009.

Participant flow — Overall Study
MilestonePlacebo + PemetrexedZD4054 + Pemetrexed
Started3630
Completed3226
Not completed44
Withdrew: Continuing study treatment44

Outcome measures

PrimaryTime to Death

Median time (in days) from randomisation until death using the Kaplan-Meier method (Calculator for survival probability)

Time frame:
Patients were followed up for survival every week for the first 3 weeks then every 3 weeks whilst on study medication until the data cut-off (17th January 2010).
Reported as:
Median · Days
Time to Death
DaysPlacebo + PemetrexedZD4054 + Pemetrexed
Time to Death193 (27 to 437)146 (19 to 427)
SecondaryProgression-free Survival

Median time (in days) from randomisation until disease progression/death using the Kaplan-Meier method

Time frame:
Tumour assessments for progression were performed at screening, every 3 weeks, Mandatory Tumour Assessment Visit (19 August 2009 ± 3 days), treatment discontinuation
Reported as:
Median · Days
Progression-free Survival
DaysPlacebo + PemetrexedZD4054 + Pemetrexed
Progression-free Survival87 (27 to 283)110 (18 to 303)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Pemetrexed—7/30 (23.3%)22/30 (73.3%)
ZD4054 + Pemetrexed—4/36 (11.1%)20/36 (55.6%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlacebo + PemetrexedZD4054 + Pemetrexed
AnaemiaBlood and lymphatic system disorders1/300/36
Febrile Bone Marrow AplasiaBlood and lymphatic system disorders1/300/36
Right Ventricular FailureCardiac disorders1/300/36
PancreatitisGastrointestinal disorders1/300/36
Upper Gastrointestinal HaemorrhageGastrointestinal disorders1/300/36
Adverse Drug ReactionGeneral disorders1/300/36
AstheniaGeneral disorders1/300/36
Metastases To Central Nervous SystemNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/300/36
Renal FailureRenal and urinary disorders1/300/36
PancytopeniaBlood and lymphatic system disorders0/301/36
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPlacebo + PemetrexedZD4054 + Pemetrexed
AnaemiaBlood and lymphatic system disorders8/307/36
NeutropeniaBlood and lymphatic system disorders5/301/36
NauseaGastrointestinal disorders2/305/36
Oedema PeripheralGeneral disorders1/304/36
Body Temperature IncreasedInfections and infestations3/302/36
Weight DecreasedInfections and infestations3/303/36
Musculoskeletal PainMusculoskeletal and connective tissue disorders3/300/36
Brain Natriuretic Peptide IncreasedInfections and infestations0/303/36
HeadacheNervous system disorders1/303/36
RashSkin and subcutaneous tissue disorders1/303/36

Baseline characteristics

Age Continuous
Age Continuous(Years)Placebo + PemetrexedZD4054 + PemetrexedTotal
Mean56.6 ± 12.0657.5 ± 10.4457 ± 11.25
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + PemetrexedZD4054 + PemetrexedTotal
Female81119
Male281947
08

Study locations

13 sites
  • research Site
    Pleven, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Varna, Bulgaria
  • Research Site
    Jicin, Czech Republic
  • Research Site
    Prague, Czech Republic
  • Research Site
    Cedex, France
  • Research Site
    Strasbourg, France
  • Research Site
    Bucharest, Romania
  • Research Site
    Cluj-Napoca, Romania
  • Research Site
    Chernivtsi, Ukraine
  • Research Site
    Kiev, Ukraine
  • Research Site
    Sumy, Ukraine
  • Research Site
    Uzngorod, Ukraine
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2008
First posted
Sep 3, 2008
Start
Aug 2008
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Jun 6, 2012
Last update
Jun 6, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00745875
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 3, 2008
Start date
Aug 2008
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Jun 6, 2012
Last update
Jun 6, 2012

Study contacts

Thomas Morris, MD
study director · AstraZeneca
Christos Chouaid, MD, Prof
principal investigator · Hospital Saint-Antoine, Cedex, France

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZD4054

Start the discussion